TWI362391B - Process for the manufacture of fused piperazin-2-one derivatives - Google Patents
Process for the manufacture of fused piperazin-2-one derivatives Download PDFInfo
- Publication number
- TWI362391B TWI362391B TW094142312A TW94142312A TWI362391B TW I362391 B TWI362391 B TW I362391B TW 094142312 A TW094142312 A TW 094142312A TW 94142312 A TW94142312 A TW 94142312A TW I362391 B TWI362391 B TW I362391B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- compound
- alkyl
- formula
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 238000004519 manufacturing process Methods 0.000 title description 2
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- -1 ethanesulfonyl Chemical group 0.000 claims description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005984 hydrogenation reaction Methods 0.000 claims description 14
- 239000007789 gas Substances 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 239000003054 catalyst Substances 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003682 vanadium compounds Chemical class 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 125000005592 polycycloalkyl group Polymers 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims description 2
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 229910052741 iridium Inorganic materials 0.000 claims 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- 239000010948 rhodium Substances 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002506 iron compounds Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 125000004354 sulfur functional group Chemical group 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- FSJSYDFBTIVUFD-XHTSQIMGSA-N (e)-4-hydroxypent-3-en-2-one;oxovanadium Chemical compound [V]=O.C\C(O)=C/C(C)=O.C\C(O)=C/C(C)=O FSJSYDFBTIVUFD-XHTSQIMGSA-N 0.000 description 1
- LFKXWKGYHQXRQA-FDGPNNRMSA-N (z)-4-hydroxypent-3-en-2-one;iron Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LFKXWKGYHQXRQA-FDGPNNRMSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- CGTNCTXIQDWSOL-UHFFFAOYSA-N 1-butoxydecane Chemical compound CCCCCCCCCCOCCCC CGTNCTXIQDWSOL-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- ZTHQBROSBNNGPU-UHFFFAOYSA-N Butyl hydrogen sulfate Chemical compound CCCCOS(O)(=O)=O ZTHQBROSBNNGPU-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 229910021576 Iron(III) bromide Inorganic materials 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229910021549 Vanadium(II) chloride Inorganic materials 0.000 description 1
- JNDDXAUSKFKLLR-DFHCBJLBSA-N [(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-benzoylsulfanylpent-3-enyl] benzoate;2-ethoxybenzamide;n-(4-ethoxyphenyl)-3-hydroxybutanamide;1,3,7-trimethylpurine-2,6-dione Chemical compound CCOC1=CC=CC=C1C(N)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.CCOC1=CC=C(NC(=O)CC(C)O)C=C1.C=1C=CC=CC=1C(=O)OCC\C(SC(=O)C=1C=CC=CC=1)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JNDDXAUSKFKLLR-DFHCBJLBSA-N 0.000 description 1
- CIARZKRWRLKYBP-UHFFFAOYSA-N [Pb]=O.[O-2].[Fe+2] Chemical compound [Pb]=O.[O-2].[Fe+2] CIARZKRWRLKYBP-UHFFFAOYSA-N 0.000 description 1
- RZHHTZWGZINIHK-UHFFFAOYSA-H [Ru+3].[Ru+3].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [Ru+3].[Ru+3].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O RZHHTZWGZINIHK-UHFFFAOYSA-H 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001785 cerium compounds Chemical class 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- IYRDVAUFQZOLSB-UHFFFAOYSA-N copper iron Chemical compound [Fe].[Cu] IYRDVAUFQZOLSB-UHFFFAOYSA-N 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- HQFQTTNMBUPQAY-UHFFFAOYSA-N cyclobutylhydrazine Chemical compound NNC1CCC1 HQFQTTNMBUPQAY-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- FZGIHSNZYGFUGM-UHFFFAOYSA-L iron(ii) fluoride Chemical compound [F-].[F-].[Fe+2] FZGIHSNZYGFUGM-UHFFFAOYSA-L 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003304 ruthenium compounds Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- GQKZRWSUJHVIPE-UHFFFAOYSA-N sec-amyl acetate Natural products CCCC(C)OC(C)=O GQKZRWSUJHVIPE-UHFFFAOYSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- FEONEKOZSGPOFN-UHFFFAOYSA-K tribromoiron Chemical compound Br[Fe](Br)Br FEONEKOZSGPOFN-UHFFFAOYSA-K 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- ITAKKORXEUJTBC-UHFFFAOYSA-L vanadium(ii) chloride Chemical compound Cl[V]Cl ITAKKORXEUJTBC-UHFFFAOYSA-L 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
1362391 九、發明說明: 【發明所屬之技術領域】 本發明係有關通式⑴之經稠合六氣峨喷_2_銅衍生物的 製法1362391 IX. Description of the invention: [Technical field of invention] The present invention relates to a method for preparing a condensed six gas jet 2_ copper derivative of the general formula (1)
R4 其中基團到V的定義如申請專利範圍和說明書所提供, 本發明尤其係有關製備7,8-二氫卻κ6_嗣衍生物的方 法。 【先前技術】 由先前技藝已知喋啶酮的冑生物是具有抗增生活性的、、舌 性物。WO 03/020722說明二氫嗓咬_衍生物用來治療腫瘤 疾病的用途和其等的製備方法。 式(I)的7,8-二氫_5hh6,衍生物是合成這些活性物 的重要中產物。一直到現在,這些衍生物都是透過還原如 下之式(II)硝基化合物的方法製成的,此種方法會形成色 彩強烈的混合物產物,因而.需要作辛苦費力的加工處理和 進行純化的步驟。 WO 96/36597說明藉添加—種鈒化合物,使用貴重金屬 觸媒行硝基化合物的催化氫化反應,同時揭示終產物為自 由胺’不包含任何的内酿胺。 105841.docR4 wherein the definition of the group to V is as provided in the scope of the patent application and the specification, the invention is particularly directed to a process for preparing a 7,8-dihydro-kappa-6-indole derivative. [Prior Art] It is known from the prior art that acaridone is an anti-proliferative activity, a tongue. WO 03/020722 describes the use of dihydrobite-derivatives for the treatment of neoplastic diseases and methods for their preparation. The 7,8-dihydro-5hh6 derivative of formula (I) is an important intermediate product in the synthesis of these actives. Up to now, these derivatives have been produced by a method of reducing a nitro compound of the following formula (II), which results in a strong color mixture product, and thus requires laborious processing and purification. step. WO 96/36597 teaches the catalytic hydrogenation of a nitro compound using a noble metal catalyst by the addition of a ruthenium compound while revealing that the final product is a free amine & does not contain any internal amine. 105841.doc
(D 1362391 【發明内容】 ,8-二氫_ 本發明之目標為提供製備式⑴化合物,特別是7 5H-嗓咬-6-酮衍生物的改良方法。 【實施方式】 本發明透過合成下文所述之式⑴化合物 上 J々法可解決 文概述的問題。 ^ 本發明因而係有關製備通式j化合物之方(D 1362391 SUMMARY OF THE INVENTION, 8-Dihydrogen _ The object of the present invention is to provide an improved process for the preparation of a compound of the formula (1), in particular a 7 5H-bite-6-one derivative. The J 々 method on the compound of the formula (1) can solve the problems outlined in the text. ^ The invention thus relates to the preparation of the compound of the formula j
(I) 其中(I) where
R R1 R3 代表係選自由氣,氟,溴,甲烷磺醯基,乙院續靡 基,三氟甲烷磺醯基,對-曱苯磺醯基, 苯基s(=o)-組成的群 代表氮或C1-C3 -烧基, 代表氫或係選自由視情況經取代之CrCu-烷基,c2 Ci2·烯基,C2_C!2-炔基和CVCi4·芳基組成之群的羞 團,或是選自由視情況經取代和/或橋連之c3-c12-環賴 基’ C3-C12-環烯基,C7-C12-聚環烷基,C7-C12-聚環詞 基’ Cs-c12_螺環烷基和飽和與不飽和之C3-C12-雜環傾 基(其含有1到2個雜原子)組成之群的基團, 105841.doc 1362391 R4, R5可以是相同或不同的基團’代表氫或視情況經取代 的^-匕-烷基,或 R4和R5—起代表可含有1到2個雜原子之2_到5_員的烷基 橋,或是 R4和R3或R5和R3—起代表飽和與不飽和的C3_C4_烷基橋, 其可視情況含有1個雜原子, 以及 Αι和八2可以是相同或不同的基團,代表_ch=或-N=,較 佳為-N=,其中式II化合物 R2The R R1 R3 representative is selected from the group consisting of gas, fluorine, bromine, methanesulfonyl, sulfonate, trifluoromethanesulfonyl, p-nonylbenzenesulfonyl, phenyl s(=o)- Representing nitrogen or a C1-C3 -alkyl group, representing hydrogen or a group selected from the group consisting of an optionally substituted CrCu-alkyl group, a c2 Ci2.alkenyl group, a C2_C!2-alkynyl group, and a CVCi4.aryl group, Or a C3-C12-cyclolyl' C3-C12-cycloalkenyl group, a C7-C12-polycycloalkyl group, a C7-C12-polycyclic group 'Cs-, which is optionally substituted and/or bridged. a group consisting of a c12-spirocycloalkyl group and a saturated and unsaturated C3-C12-heterocyclic palladium group having from 1 to 2 heteroatoms, 105841.doc 1362391 R4, R5 may be the same or different The group ' represents hydrogen or optionally substituted ^-匕-alkyl, or R4 and R5 together represent an alkyl bridge of 2 to 5 members which may contain 1 to 2 heteroatoms, or R4 and R3 Or R5 and R3 together represent a saturated and unsaturated C3_C4_alkyl bridge, which optionally contains 1 heteroatom, and Αι and 八2 may be the same or different groups, representing _ch= or -N=, Preferably, -N=, wherein compound R2 of formula II
(Π) 其中 r1-r5和Αι ’八2具有所述的定義並且 R代表Ci-c4-院基, a) 在氫化觸媒存在下使用氫行氫化反應,以及 b) 添加鋼’鐵或釩的化合物, 其中步驟a)和b)可同時或相繼發生。 一較佳方法中,式II化合物的氫化反應是在氫化觸媒與 銅’鐵或飢化合物的存在下直接進行的,形成式I化合 物0(Π) where r1-r5 and Αι '八2 have the stated definition and R represents Ci-c4-yard, a) hydrogen hydrogenation in the presence of a hydrogenation catalyst, and b) addition of steel 'iron or vanadium Compounds in which steps a) and b) can occur simultaneously or sequentially. In a preferred method, the hydrogenation of the compound of formula II is carried out directly in the presence of a hydrogenation catalyst and copper iron or a starvation compound to form a compound of formula I.
10584i.doc 1362391 一尤佳方法中,第一氫化步驟a)之後首先獲得式ΠΙ的中 產物,其可視情況作離析,10584i.doc 1362391 In a preferred method, the first product of the formula is first obtained after the first hydrogenation step a), which can be isolated as appropriate.
(in) 隨後在氫化觸媒及銅、鐵或釩化合物存在下進一步還原, 形成式I化合物 R Η(in) subsequently further reduced in the presence of a hydrogenation catalyst and a copper, iron or vanadium compound to form a compound of formula I R Η
翻,纪和雷氏錄)組成的群的方法也是偏好的。鉑屬尤] 者。鉑可於載體上以金屬或氧化物態(如氧化鉑)的形式4 用,載體例如像是活化炭,二氧化矽,氧化鋁,碳酸鈣 碌酸約,較約,硫酸鋇,二氧化鈦,氧化鎖,氧化鐵 氧化鉛,硫酸錯4碳酸Μ,並且可視情況額外捧雜硫^ 船。較佳的載體物料活化炭,二氧切或氧化紹。 較佳的銅化合物為其中鋼為氧化態工或Η的化合物,例; 銅的 i 化物,譬如 CuC卜 CuCl2,CuBr,cuB〇,cunThe method of group consisting of turn, Ji and Lei Shi is also preferred. Platinum is especially good. The platinum may be used in the form of a metal or an oxide state (e.g., platinum oxide) on a support such as activated carbon, cerium oxide, aluminum oxide, calcium carbonate, or similar, barium sulfate, titanium oxide, oxidation. Lock, iron oxide lead oxide, sulfuric acid wrong 4 barium carbonate, and depending on the situation, additional sulfur sulfur ^ boat. Preferred carrier materials activate carbon, dioxin or oxidation. Preferred copper compounds are those in which the steel is in an oxidized state or a ruthenium, for example; a copper compound such as CuCb CuCl2, CuBr, cuB〇, cun
CuS04較佳的鐵化合物為其中鐵為氧化態Η或HI的 105841.doc 1362391. 物,例如鐵的鹵化物,譬如FeCl2,FeCl3,FeB〇, FeBr3,FeF2或其他的鐵化合物’譬如FeS〇4,Fep〇4或 Fe(aCaC)2。較佳的釩化合物為其中釩為氧化態〇 , π , πι, IV或V的化合物,例如無機或有機化合物或錯合物,像是 v203 ’ v2o5 ’ v2〇4 ’ Na4V〇4,NaV〇3,NH4V〇3,v〇ci2, v〇Cl3,V〇S〇4,VCl2,vci3,雙(1_ 苯基 _13 丁烧二酸醋) 叙’三異丙乾化物氧化Μ ,乙酿基丙_酸叙(ΙΙΙ)[ν(·)3] 或是乙酿基丙嗣酸醋氧化叙(IV)[vo(acae)2]。乙酿基丙嗣 酸酯氡化飢(IV)[VO(acac)2]為尤佳者。 銅’鐵或IM匕合物可依喜好在氫化反應開始時直接使 用’或在式(III)的中間物形成後使用。 其中氫化觸媒的添加量以所用式(II)化合物為基準介於 0.1和10重量%間的方法也是合適的。 同樣。適的方法為其中銅,鐵或鈒化合物的用量以所用 式(II)化合物為基準介於〇 〇1和1〇重量%間。 較佳的方法也包括其中反應是在某一種溶劑中進行者, 此溶劑選自由兩性非質子性的溶劑(例如二甲基甲酿胺, 二甲基乙醯胺’ Ν·甲基吡咯啶酮,二甲亞砜或環丁颯” 醇(例如甲醇,乙醇 蚌1-丙私,2·丙醇,丁烷和戊烷之各種 的異構醇);醚(例如二乙醚’甲基第三丁基醚,四氫呋 喃,2-甲基四氫吱喃’二哼烷或二甲氧基乙烷旨(例如 乙酉夂乙§曰’乙酸2-丙酯或乙酸卜丁酯);酮(例如丙酮,曱 乙酮:甲基異丁酮);羧酸(例如乙酸);非極性的溶劑(例 如甲苯,二甲苯,環己烷或甲基環己烷),以及乙腈,二 105841.doc .1362391 氯甲烷和水組成的群組。 可使用溶劑的混合物。 較佳的方法也包括為其令反應溫度介於〇。〇和150°C間, 尤佳為介於2 0 °C和10 0 °C之間。 較佳的方法也包括為其中氫的壓力為1巴到1〇〇巴。 本發明進一步係有關式(III)化合物The preferred iron compound of CuS04 is 105841.doc 1362391. In which iron is oxidized or HI, such as iron halides, such as FeCl2, FeCl3, FeB〇, FeBr3, FeF2 or other iron compounds such as FeS〇4 , Fep〇4 or Fe(aCaC)2. Preferred vanadium compounds are compounds in which vanadium is in the oxidized state of ruthenium, π, π, IV or V, such as inorganic or organic compounds or complexes, such as v203 'v2o5 'v2〇4 'Na4V〇4, NaV〇3 , NH4V〇3, v〇ci2, v〇Cl3, V〇S〇4, VCl2, vci3, bis(1_phenyl_13 butyl sulphuric acid vinegar) _ 酸 ΙΙΙ (ΙΙΙ) [ν (·) 3] or ethoxylated vinegar vinegar oxidation (IV) [vo (acae) 2]. Ethyl acetoacetate (IV) [VO (acac) 2] is particularly preferred. The copper 'iron or IM conjugate can be used as it is at the beginning of the hydrogenation reaction' or after the intermediate of the formula (III) is formed. A method in which the amount of the hydrogenation catalyst added is between 0.1 and 10% by weight based on the compound of the formula (II) used is also suitable. same. A suitable method is one in which the amount of the copper, iron or cerium compound is between 〇1 and 1% by weight based on the compound of the formula (II) used. Preferably, the method further comprises the step wherein the reaction is carried out in a solvent selected from the group consisting of amphoteric aprotic solvents (e.g., dimethylamine, dimethylacetamide, hydrazine, methylpyrrolidone). , dimethyl sulfoxide or cyclobutyl hydrazine alcohol (eg methanol, ethanol hydrazine 1-propanol, 2 · propanol, butane and pentane various isomeric alcohols); ether (eg diethyl ether 'methyl third Butyl ether, tetrahydrofuran, 2-methyltetrahydrofuran 'dioxane or dimethoxyethane (for example, 2-ethyl acetate or 2-butyl acetate); ketone (such as acetone) , acetophenone: methyl isobutyl ketone); carboxylic acid (such as acetic acid); non-polar solvent (such as toluene, xylene, cyclohexane or methylcyclohexane), and acetonitrile, two 105841.doc .1362391 a group consisting of methyl chloride and water. A mixture of solvents can be used. The preferred method also includes a reaction temperature between 〇.〇 and 150 ° C, particularly preferably between 20 ° C and 10 0 °. Between C. The preferred method also includes a pressure of 1 bar to 1 bar of hydrogen therein. The invention further relates to a compound of formula (III)
R2 OHR2 OH
其中R1到R5具有所述的定義。 較佳的式(III)化合物為那些其中、和、是相同且代表 •N=者0 此等反應以傳統的方式,例如透過萃取純化的步驟會沉 澱及結晶的方法逐步完成。Wherein R1 to R5 have the definitions described. Preferred compounds of formula (III) are those in which, and are the same and represent • N = 0. These reactions are carried out in a conventional manner, for example, by precipitation and crystallization by extraction purification steps.
根據本發明之化合物可以各別的光學異構物,各別鏡相 異構物的混合物,非鏡相異構物或消旋物的形式,互變異 構物的形式以及自由鹼或包含酸之對應的酸加成鹽(像是 例如包含氫齒酸的酸加^ ’譬#氣氯酸或氯漠酸,或有 機酸,如草酸,反丁烯二酸,氣化_ ^p *公 ^ 礼化一乙酸或甲烷磺酸)的 形式存在。 團的部份者)有包含1到 尤佳為1-4個碳原子)的 院基的實例(包括那些是其他基 12個碳原子(較佳為1-6個碳原子, 105841.doc 1362391 支鏈和非支鏈型的烷基’例如是:甲基,乙基,丙基,丁 基’戊基,己基’庚基’辛基,壬基,癸基和十二院基。 除非另有聲明’否則上述的命名丙基,丁基,戊基,己 基,庚基,辛基,壬基,癸基和十二烷基是包括所有可能 的異構型。例如,丙基包括兩種異構基團正·丙基和異丙 基,丁基包括正-丁基,異-丁基,第二丁基和第三丁基, 戊基包括異戊基,新戊基等。The compounds according to the invention may be in the form of individual optical isomers, mixtures of individual mirror isomers, non-mirror isomers or racemates, tautomeric forms and free bases or acids. Corresponding acid addition salts (such as, for example, an acid containing hydrogen dentate plus 譬 譬 # 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯 氯The form of liquefied monoacetic acid or methanesulfonic acid) exists. Part of the group) has examples of yards containing 1 to 1-4 carbon atoms (including those of other groups of 12 carbon atoms (preferably 1 to 6 carbon atoms, 105841.doc 1362391) Branched and unbranched alkyl groups are, for example, methyl, ethyl, propyl, butyl 'pentyl, hexyl'heptyl'octyl, decyl, decyl and decyl. Unless otherwise There are statements 'otherwise the above-mentioned names propyl, butyl, pentyl, hexyl, heptyl, octyl, decyl, decyl and dodecyl are all possible isomeric forms. For example, propyl includes two The isomeric group is n-propyl and isopropyl, and the butyl includes n-butyl, iso-butyl, t-butyl and t-butyl groups, and the pentyl group includes isopentyl, neopentyl and the like.
上述烷基中,一或一個以上的氫原子可視情況被其它的 基團取代。例如這些烷基可被氟取代。烷基的所有氲原子 也可能通通被取代。Among the above alkyl groups, one or more hydrogen atoms may be optionally substituted by other groups. For example, these alkyl groups can be substituted by fluorine. All of the ruthenium atoms of the alkyl group may also be replaced by all.
烷基橋的實例除非另有聲明,否則為包含2到5個碳原子 的支鏈和非支鏈型的烷基,例如伸乙基,伸丙基,異伸丙 基’正-伸丁基’異-丁基’第二丁基和第三丁基等的橋 基。尤佳者為伸乙基,#丙基和伸丁基的橋基。上述的烷 基橋基中’有un個c原子可視情況被―或—個以上的雜 原子取代,雜原子選自氧,氮或硫。 烯基的實例(包括那些是其他基團的部份者)有包含2 12個碳原子(較佳為2·6個碳原子,尤佳為2_3個碳原子) 支鏈和非支鏈型的縣,前提為其等具有至少—個雙鍵 ^下所示相舉者:乙縣,㈣基,Τ稀基,戊稀 ^除非另有聲明’否則上述的命名丙稀基,丁稀基等 括所有可能的異構型。例如’丁埽基包括1.丁稀基,2_· 烯基,3-丁烯基,i•甲基尚稀 ,土1〒基-2-丙烯基,: T暴-1-丙烯基,2-甲篇系,咕, 甲暴丙烯基和^乙基-1-乙烯基。 105841.doc ⑧ •12- .丄观別 上述烯基令,除非另有聲明,否則一或一個以上的氫原 Γ可視情況被其它的基團取代。例如這些烯基可被齒原子 氣取代#基的所有氫原子也可能通通被取代。 炔基的實例(包括那些是其他基團的部份者)有包含2到 12個碳原子的支鏈和非支鏈型的炔基,前提為其等具有至 少一個參鍵’例如乙炔基,丙炔基,丁炔基,戊炔基己 炔基等,較佳為乙炔基或丙炔基。Examples of alkyl bridges are branched and unbranched alkyl groups containing from 2 to 5 carbon atoms, such as ethyl, propyl, and exopropyl propyl-n-butyl, unless otherwise stated. A bridging group of 'iso-butyl' dibutyl and tert-butyl groups. Particularly preferred are the bridging groups of ethyl, #propyl and butyl. In the above alkyl bridging group, 'unless c atoms may be optionally substituted by - or more than one hetero atom selected from oxygen, nitrogen or sulfur. Examples of alkenyl groups (including those which are part of other groups) have 2 12 carbon atoms (preferably 2·6 carbon atoms, preferably 2 to 3 carbon atoms) branched and unbranched County, premise that it has at least one double bond ^ shown below: B County, (four) base, Τ 基, 戊 ^ ^ unless otherwise stated 'other than the above named acryl, butyl, etc. Includes all possible isomeric forms. For example, 'butyryl group includes 1. butylon, 2_. alkenyl, 3-butenyl, i•methyl is still rare, soil 1 fluorenyl-2-propenyl, T storm-1-propenyl, 2-methyl Department, 咕, A storm propylene and ^ ethyl-1-vinyl. 105841.doc 8 •12- . . . to observe the above alkenyl orders, unless otherwise stated, one or more hydrogenogens may be replaced by other groups as appropriate. For example, all of the hydrogen atoms of these alkenyl groups which may be substituted by a tooth atom may also be substituted. Examples of alkynyl groups (including those which are part of other groups) have branched and unbranched alkynyl groups containing from 2 to 12 carbon atoms, provided that they have at least one reference group such as an ethynyl group, Propynyl, butynyl, pentynylhexynyl and the like are preferably ethynyl or propynyl.
上述炔基中,除非另有聲明,否則一或一個以上的氫原 子可視If况被其匕的基團取代。例如這些炔基可為氣取代 者。炔基的所有氫原子也可能通通被取代。Among the above alkynyl groups, unless otherwise stated, one or more hydrogen atoms may be substituted by the group to which they are derived. For example, these alkynyl groups can be gas replacers. All hydrogen atoms of the alkynyl group may also be substituted.
方基乙詞代表包含6到14個碳原子(較佳為6或1〇個碳原 子)的芳香環系統,最好是苯基,除非另有聲明,否則可 例如帶有一或一個以上以下的取代基:〇H,n〇2,cn, 〇Me,_〇CHF2 ’ -OCf3,齒素(較佳為敦或氣),c「Ci〇·烧 基(較佳為CrC5·烷基,尤其是^-(:3-烷基,尤佳為甲基或 土) 〇 Ci C3-貌基(車交佳為_〇_甲基或_〇_乙基),_c〇〇h ’ -C00-Ci-C4-烷基(較佳為_c〇〇甲基或c〇〇_乙基) -CONH2。 環烷基的實例為包含3_12個碳原子的環烷基,例如環丙 基,環丁基,環戊基,環己基,環庚基或環辛基,較佳為 環丙基,環戊基或環己基,同時每個上述的環烷基也可視 情況帶有一或一個以上的取代基,例如是:,n〇2 , CN,OMe ’ ,-0(^3或齒素(較佳為氟或氯),Ci_ c〗〇-烷基(較佳aCl_C5_烷基,尤其是Ci_C3_烷基,尤佳為 105841.doc •13- ⑧ 1362391 甲基或乙基),-0-CrC3-烷基(較佳為-〇_甲基或_〇乙 基),-COOH,-C00-CVC4-烷基(較佳為-C00·甲基或 -coo-乙基)或-conh2。環烷基尤佳的取代基為=〇, 〇H, 甲基或F。 環烯基的實例為包含3-12個碳原子的環烯基,其具有至 少一個雙鍵,例如環丙烯基,環丁烯基,環戊烯基,環己 烯基或環庚烯基,較佳為環丙烯基,環戊烯基或環己烯 基,同時每個上述的料基可視情況帶有_或一個以上的 取代基。 =◦代表以雙鍵連接的氧原 雜環烧基的實例,除非定義中^有聲明,為3·到12-員 (較佳為5 6-或7.貝)之飽和或不飽和的雜環,其可包含 氣,氧或硫的雜原子,例如四氮峡畴,四氮咬唾闕,γ· 丁 内Sa α辰南γ·痕喃,二氧戊環,四氫旅喃,二氧雜環 己烷,二氫遠吩,硫味,二硫味,峨咯琳,吡咯啶"比唑 淋’…,琳"米唾咬,四嗤,六氫㈣十井, ㈣"比啡,六氫t井,三,井,四呼,嗎琳,硫代嗎琳, 地西泮(diaZePam),十井,四氫十井基’異‘坐和,比嗤 咬,較佳為嗎琳,吼吹β ^ ’哪叫啶,六氫吡啶或六氫吡畊,同時該 雜環可視情況帶有例如c Γ q列如I丨-C4·烷基,較佳為甲基,乙基或 丙基的取代基。 聚環院基的實例為視情況經取代的雙_,三_,四·或五環 的環烧基’例如苹,2?,立 ’ ’-辛烷’ 2,2,1-庚烷或金剛烷。聚 環稀基的實例為視情況經橋 倚連和/或經取代之8員的雙-, 105841.doc 如果料基,較佳為雙料基或三環稀基, 如果其#包含至少—個雙鍵的話,例如為降冰片稀。 螺说基的f例為視情況經取代的螺環c5.c12-烧基。 通*代表a,氣,溴或蛾,較佳為I,氯或漠,尤 佳為氣0 *取代基R可代表選自由氣,氟,溪,曱烧績醯基,乙烧 %酿基’二⑨甲烧❹基和對·甲苯罐醯基組成之群的基 團,較佳為氣。 取代基R可代表氫或Ci_C3烧基,較佳為氣。 取代基R3可代表氫, 或選自由視情況經取代之Ci_Ci2_烷基,C2_Ci2·烯基, C2_Cl2_炔基,和C6-Cl4·芳基組成之群的基團,較佳為苯 基,或是選自由視情況經取代和/或橋連之C3_Ci2環烷基 (較佳為環戊基),CVCt環烯基,c7_Ci2•聚環烷基,C7_ ciz-聚環烯基,Cs-C^-螺環烷基和飽和與不飽和之c3_Ci2_ 雜環烷基(其包含1到2個雜原子)組成之群的基團。 取代基R4, R5可以是相同或不同的基團並且可代表氫, 或視情況經取代的Ci-C6-烷基, 或R4和R5—起代表可包含1到2個雜原子之2_到5_員的烧 基橋, 或是R4和R3或R5和R3 —起代表飽和與不飽和的C3_C4_烷 基橋’其可視情況包含1個雜原子β 八!和八2可以是相同或不同的基團,代表,較 佳為-Ν=。 105841.doc 1362391The aryl group represents an aromatic ring system containing from 6 to 14 carbon atoms, preferably 6 or 1 carbon atoms, preferably a phenyl group, which may, for example, have one or more of the following, unless otherwise stated. Substituents: 〇H, n〇2, cn, 〇Me, _〇CHF2 '-OCf3, dentate (preferably or gas), c"Ci〇·alkyl (preferably CrC5·alkyl, especially Is ^-(:3-alkyl, especially methyl or soil) 〇Ci C3-morphyl (car jia is _〇_methyl or _〇_ethyl), _c〇〇h ' -C00- Ci-C4-alkyl (preferably _c〇〇methyl or c〇〇_ethyl)-CONH2. Examples of cycloalkyl groups are cycloalkyl groups containing 3 to 12 carbon atoms, such as cyclopropyl, cyclobutane Or a cyclopentyl group, a cyclohexyl group, a cycloheptyl group or a cyclooctyl group, preferably a cyclopropyl group, a cyclopentyl group or a cyclohexyl group, and each of the above cycloalkyl groups may optionally have one or more substituents. , for example: n〇2 , CN, OMe ' , -0 (^3 or dentate (preferably fluorine or chlorine), Ci_ c 〇-alkyl (preferably aCl_C5_alkyl, especially Ci_C3_ Alkyl, especially preferably 105841.doc • 13- 8 1362391 methyl or ethyl) ,-0-CrC3-alkyl (preferably -〇-methyl or 〇ethyl), -COOH, -C00-CVC4-alkyl (preferably -C00.methyl or -coo-ethyl) Or -conh2. A preferred substituent of the cycloalkyl group is 〇, 〇H, methyl or F. Examples of cycloalkenyl groups are cycloalkenyl groups having 3 to 12 carbon atoms which have at least one double bond, for example a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group or a cycloheptenyl group, preferably a cyclopropenyl group, a cyclopentenyl group or a cyclohexenyl group, and each of the above-mentioned base groups may be optionally used. With _ or more than one substituent. = ◦ represents an example of an oxo-heterocyclic group bonded by a double bond, unless stated in the definition, from 3 to 12 members (preferably 5 6- or 7) a saturated or unsaturated heterocyclic ring which may contain a hetero atom of gas, oxygen or sulfur, such as a tetranitrogen domain, a tetrazole, a γ·丁内 Sa α辰南γ·, a second Oxolane, tetrahydrobine, dioxane, dihydro far thiophene, sulfur, disulfide, 峨 琳 琳, pyrrolidine "Bizolin'..., Lin " rice squirt, four Hey, six hydrogen (four) ten wells, (four) " than the brown, six hydrogen wells, three, , four calls, hualin, thio dailin, diazepam (diaZePam), ten wells, tetrahydrogen well base 'different' sitting and, than bite, preferably yin, 吼 blowing β ^ 'Which Pyridine, hexahydropyridine or hexahydropyridinium, and the heterocyclic ring may optionally have, for example, a c Γ q column such as I 丨-C4.alkyl, preferably a methyl, ethyl or propyl substituent. An example of a hospital base is a double-, triple-, tetra- or pentacyclic ring-burning group as the case may be substituted, such as ping, 2?, ligating ''octane' 2,2,1-heptane or adamantane . An example of a polycyclic ring is a bridge-dependent and/or substituted 8-membered double-, 105841.doc if a substrate, preferably a double or a tricyclic, if its # contains at least one In the case of a double bond, for example, the ice sheet is thin. The f example of the spiro group is a spiro c5.c12-alkyl group which is optionally substituted. ** represents a, gas, bromine or moth, preferably I, chlorine or desert, especially preferably gas 0. The substituent R may be selected from the group consisting of gas, fluorine, sulphur, sulphur, and sulphur. The group of the group consisting of a sulphur group and a sulphur group is preferably gas. The substituent R may represent hydrogen or a Ci_C3 alkyl group, preferably a gas. The substituent R3 may represent hydrogen, or a group selected from the group consisting of Ci_Ci2_alkyl, C2_Ci2. alkenyl, C2_Cl2-alkynyl, and C6-Cl4.aryl optionally substituted, preferably phenyl, Or a C3_Ci2 cycloalkyl group (preferably cyclopentyl) which is optionally substituted and/or bridged, CVCt cycloalkenyl, c7_Ci2•polycycloalkyl, C7_ ciz-polycycloalkenyl, Cs-C a group of a group consisting of a spirocycloalkyl group and a saturated and unsaturated c3_Ci2_heterocycloalkyl group (which contains 1 to 2 hetero atoms). The substituents R4, R5 may be the same or different groups and may represent hydrogen, or optionally substituted Ci-C6-alkyl, or R4 and R5 together represent 2 to 2 heteroatoms. The 5_ member's base bridge, or R4 and R3 or R5 and R3 together represent a saturated and unsaturated C3_C4_alkyl bridge' which may optionally contain 1 heteroatom β VIII! And 八2 may be the same or different groups, representative, preferably -Ν=. 105841.doc 1362391
R6可代表C^-C4·烧基,較佳為甲基或乙基。 式(III)化合物可根據文獻已知的方法製備, 例如類似 WO 03/020722中所述的合成法β 通式(I)的化合物尤其可依以下的合成實例製借。 明。然而, 這些實例只是作為用來說明本發明流程的例子,而非將本 發明範圍限制為這些實例的内容β 一般的合成方式以流程圖表示。 流程圖1R6 may represent a C^-C4.alkyl group, preferably a methyl group or an ethyl group. The compound of the formula (III) can be produced according to a method known in the literature, for example, a synthesis method similar to that described in WO 03/020722. The compound of the formula (I) can be specifically obtained by the following synthesis examples. Bright. However, these examples are merely examples for explaining the flow of the present invention, and the scope of the present invention is not limited to the contents of the examples. Flow chart 1
(7 R)-2 -氯-8-環戊基_7-乙基-5-經基- 7,8-二氫-5Η-嗓咬-6-嗣 的合成法 105841.doc 16. ⑧ 1362391Synthesis of (7R)-2-chloro-8-cyclopentyl_7-ethyl-5-carbyl-7,8-dihydro-5Η-嗓 bit-6-嗣 105841.doc 16. 8 1362391
將30克(84_2毫莫耳)的1溶解於3〇〇亳升的四氫呋喃中並 添加3克的Pt/C(5%)。饥及4巴的氫壓下氣化反應混合物 五小時。過渡出觸媒並用約30毫升的四氣咬喃清洗。減壓 • 下以蒸發的方式濃縮濾液。獲得25.6克為黃色固體的產物 2。 ^-NMR (400 MHZ) (DMSOd6 ): δ 11.〇5 (bs 1H); y.85 (s 1H); 4.47-4.45 (dd 1H); 4.16-4.08 (t lH); 1.95-1.67 (m 10H); 0.80-0.73 (t 3H) (7R)-2 -氣-8·環戍基-7-乙基- 7,8-二氩- 5H-嗓咬晒的合成法30 g (84-2 mmol) of 1 was dissolved in 3 liters of tetrahydrofuran and 3 g of Pt/C (5%) was added. The gasification reaction mixture was starved for 5 hours under hydrogen pressure of 4 bar. The catalyst was transferred out and washed with about 30 ml of four gas. Decompression • Concentrate the filtrate by evaporation. 25.6 g of product 2 were obtained as a yellow solid. ^-NMR (400 MHZ) (DMSOd6): δ 11.〇5 (bs 1H); y.85 (s 1H); 4.47-4.45 (dd 1H); 4.16-4.08 (t lH); 1.95-1.67 (m Synthesis method of 10H); 0.80-0.73 (t 3H) (7R)-2 - gas-8·cyclodecyl-7-ethyl-7,8-di-argon- 5H-嗓
3 將5.22克(17.6毫莫耳)的2溶解於55毫升的四氫呋喃中。 添加520毫克的Pt-C( 5%)和250毫克的乙醯基丙酮酸酯氧化 釩(IV)。20°C及4巴的氫壓下氩化該反應混合物六小時。過 濾出觸媒並用約15毫升的四氫呋喃清洗。減壓下以蒸發的 105841.doc -17- ⑧ 1362391 方式濃縮濾液。獲得5.0克為黃色粉末的產物3。 H-NMR (400 MHz) (DMS〇d6): δ 11.82 (bs 1H); 7.57 (s 1H); 4.24-4,21 (dd 1H); 4.17-4.08 (m ih); 1.97-1.48 (m l〇H); 0.80-0.77 (t 3H)。 (7R)-2-氣-8-環戊基-7-乙基-7,8-二氫-5U-喋咬-6-酮的合成法 將70克的pt/C(5%)加入700克(1·96莫耳)溶於7〇〇毫升四 氫呋喃的溶液中。35〇C及4巴的氫壓下氫化該反應混合物 2·5小時直到氫的攝取停止為止。打開高壓釜並添加35克 的乙醯基丙酮酸酯氧化釩(IV)。混合物於3 5。〇及4巴的氫壓 下再行氫化2.5小時。過濾並用四氫呋喃清洗殘餘物。減 壓下以蒸發的方式濃縮遽液。將殘餘物溶解於2.7 5升的丙 酮中’以及藉添加等量的去礦質水沉澱出殘餘物。所得固 體作吸遽並用丙闕/水(1:1)的混合物清洗,然後用第三丁 基曱基醚清洗。乾燥後獲得551毫克的產物 (7R)-2-氣-8-環戊基-7-已基-7,8-二氫-5H-嗓咬-6-酮的合成法 將30克(84毫莫耳)的1溶解於300毫升的四氫呋喃中。添 加3克的Pt/C(5%)和1.5克的乙酿基丙酮酸醋氧化鈒(iv)。 3 5°C及4巴的氫壓下氫化該反應混合物24小時直到反應完 全為止。過濾溶液’用四氫呋喃清洗殘餘物,並於減壓下 以蒸發的方式濃縮壚液。將殘餘物溶解於11 8毫升的丙_ 中’以及藉添加等量的去礦質水沉澱出殘餘物。所得固體 作吸遽並用丙酮/水(1:1)的混合物清洗,然後用第=丁美 曱基醚清洗。乾燥後獲得18克的產物3。 (7R)-2-氣-7- 6基-8-異丙基-7,8-二氫-5H-嗓咬-6·_的合成法 105841.doc 1S ⑧ 13623913 5.22 g (17.6 mmol) of 2 was dissolved in 55 ml of tetrahydrofuran. Add 520 mg of Pt-C (5%) and 250 mg of acetal pyruvate to oxidize vanadium (IV). The reaction mixture was argonized under hydrogen pressure at 20 ° C and 4 bar for six hours. The catalyst was filtered off and washed with about 15 ml of tetrahydrofuran. The filtrate was concentrated under reduced pressure in the form of evaporated 105841.doc -17-8 1362391. 5.0 g of product 3 was obtained as a yellow powder. H-NMR (400 MHz) (DMS 〇d6): δ 11.82 (bs 1H); 7.57 (s 1H); 4.24-4,21 (dd 1H); 4.17-4.08 (m ih); 1.97-1.48 (ml〇 H); 0.80-0.77 (t 3H). Synthesis of (7R)-2- gas-8-cyclopentyl-7-ethyl-7,8-dihydro-5U-indole-6-one 70 grams of pt/C (5%) was added to 700 Glucose (1·96 mol) was dissolved in 7 ml of tetrahydrofuran. The reaction mixture was hydrogenated under a hydrogen pressure of 35 ° C and 4 bar for 2.5 hours until the hydrogen uptake was stopped. The autoclave was opened and 35 g of vanadyl pyruvate oxide vanadium (IV) was added. The mixture was at 3 5 . Hydrogenation was carried out for 2.5 hours under hydrogen pressure at 4 bar. Filter and wash the residue with tetrahydrofuran. The mash is concentrated by evaporation under reduced pressure. The residue was dissolved in 2.7 5 liters of acetone and the residue was precipitated by adding an equal amount of demineralized water. The resulting solid was sucked and washed with a mixture of propylene/water (1:1) and then washed with a third butyl decyl ether. After drying, 551 mg of the product (7R)-2- gas-8-cyclopentyl-7-hexyl-7,8-dihydro-5H-indole-6-one was obtained in a 30 g method (84 m). 1 of Mohr) was dissolved in 300 ml of tetrahydrofuran. Add 3 grams of Pt/C (5%) and 1.5 grams of ruthenium ruthenium acetate (iv). The reaction mixture was hydrogenated at 5 ° C and 4 bar under hydrogen pressure for 24 hours until the reaction was complete. The solution was filtered, and the residue was washed with tetrahydrofuran, and the mixture was concentrated and evaporated. The residue was dissolved in 11 8 mL of propylidene and the residue was precipitated by adding an equivalent amount of demineralized water. The resulting solid was taken up as a suction and washed with a mixture of acetone/water (1:1) and then washed with hexanes. After drying, 18 grams of product 3 were obtained. Synthesis of (7R)-2- gas-7- 6-yl-8-isopropyl-7,8-dihydro-5H-bite-6·_ 105841.doc 1S 8 1362391
將10克(316毫莫耳)的4溶解於800毫升的四氫呋喃和200 毫升的異丙醇中。添加10克的Pt/C(5°/〇)和5克的乙醯基丙 酮酸酯氧化釩(IV)。35°C及4巴的氫壓下氫化該反應混合物 24小時直到反應完全為止。過濾溶液,並讓濾液完全蒸發 直到結晶開始形成為止。添加15 0毫升的異丙醇,並將懸 浮液加熱至70-80°C直到完全溶解為止。添加6〇〇毫升的去 礦質水後,產物開始有結晶的反應。作吸濾並用去礦質水 清洗。乾燥後獲得68克的產物5。 'H-NMR (400 MHz) (DMSOd6): δ l〇.8l (bs 1H); 7.56 (s 1H); 4.37-4.24 (m 2H); 1.89-1.65 (m 2H); 1.34-1.31 (m10 g (316 mmol) of 4 was dissolved in 800 ml of tetrahydrofuran and 200 ml of isopropanol. 10 g of Pt/C (5 ° / 〇) and 5 g of acetamidopropionate vanadium (IV) oxide were added. The reaction mixture was hydrogenated at 35 ° C and 4 bar under hydrogen pressure for 24 hours until the reaction was completed. The solution was filtered and the filtrate was allowed to completely evaporate until crystallization began to form. 150 ml of isopropanol was added and the suspension was heated to 70-80 ° C until completely dissolved. After the addition of 6 liters of demineralized water, the product began to crystallize. Filter by suction and wash with demineralized water. 68 g of product 5 were obtained after drying. 'H-NMR (400 MHz) (DMSOd6): δ l〇.8l (bs 1H); 7.56 (s 1H); 4.37-4.24 (m 2H); 1.89-1.65 (m 2H); 1.34-1.31 (m
6H); 0.80-0.73 (t 3H) 10584 丨.doc 19-6H); 0.80-0.73 (t 3H) 10584 丨.doc 19-
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004058337A DE102004058337A1 (en) | 2004-12-02 | 2004-12-02 | Process for the preparation of fused piperazin-2-one derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200628471A TW200628471A (en) | 2006-08-16 |
| TWI362391B true TWI362391B (en) | 2012-04-21 |
Family
ID=35923724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094142312A TWI362391B (en) | 2004-12-02 | 2005-12-01 | Process for the manufacture of fused piperazin-2-one derivatives |
Country Status (34)
| Country | Link |
|---|---|
| US (9) | US7238807B2 (en) |
| EP (2) | EP1819706B1 (en) |
| JP (1) | JP5164574B2 (en) |
| KR (2) | KR101362131B1 (en) |
| CN (3) | CN102093361B (en) |
| AR (1) | AR053100A1 (en) |
| AU (1) | AU2005311308B2 (en) |
| BR (1) | BRPI0518601A2 (en) |
| CA (1) | CA2588857C (en) |
| CL (1) | CL2013002895A1 (en) |
| CY (1) | CY1113625T1 (en) |
| DE (1) | DE102004058337A1 (en) |
| DK (2) | DK2436685T3 (en) |
| EA (1) | EA012624B1 (en) |
| ES (2) | ES2548680T3 (en) |
| HR (1) | HRP20120980T1 (en) |
| HU (1) | HUE027689T2 (en) |
| IL (1) | IL183568A (en) |
| ME (1) | ME01470B (en) |
| MX (1) | MX2007006549A (en) |
| MY (1) | MY147459A (en) |
| NO (1) | NO20072283L (en) |
| NZ (1) | NZ556182A (en) |
| PE (2) | PE20090488A1 (en) |
| PL (2) | PL2436685T3 (en) |
| PT (1) | PT1819706E (en) |
| RS (1) | RS52533B (en) |
| SG (2) | SG141461A1 (en) |
| SI (1) | SI1819706T1 (en) |
| TW (1) | TWI362391B (en) |
| UA (1) | UA89390C2 (en) |
| UY (1) | UY29233A1 (en) |
| WO (1) | WO2006058876A1 (en) |
| ZA (1) | ZA200703368B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004029784A1 (en) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments |
| DE102004033670A1 (en) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pyridodihydropyrazinone, process for its preparation and its use as a medicament |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1630163A1 (en) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, methods for their preparation and their use as drugs |
| EP1632493A1 (en) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridine derivatives, methods for their preparation and their use as drugs |
| DE102004058337A1 (en) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of fused piperazin-2-one derivatives |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US7622463B2 (en) | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| JP4958461B2 (en) * | 2006-03-30 | 2012-06-20 | 富士フイルム株式会社 | Near-infrared absorbing dye-containing curable composition |
| AU2008211729A1 (en) | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors |
| CA2695406A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| CN102020643A (en) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | dihydropteridine ketone derivative, and preparation method and medicinal application thereof |
| ES2567280T3 (en) * | 2009-09-25 | 2016-04-21 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| EP2480553A2 (en) | 2009-09-25 | 2012-08-01 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| ES2533042T3 (en) | 2011-02-25 | 2015-04-07 | Takeda Pharmaceutical Company Limited | N-substituted oxazinopteridines and N-substituted oxazinopteridinones |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| UY34893A (en) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | DERIVATIVES OF AZAINDOL |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| UY35945A (en) | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | DERIVATIVES OF AZAINDOL |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4032639A (en) * | 1976-03-22 | 1977-06-28 | American Home Products Corporation | 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension |
| US4182872A (en) * | 1976-03-22 | 1980-01-08 | American Home Products Corporation | 4-(Lower)alkyl-1-(o-nitrophenyl)piperazine-2-carboxylic acid chemical intermediates |
| NL8303657A (en) | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | SOLUTION, STABLE, AQUEOUS, AQUEOUS, CONTAINING SOLUTION OF CISPLATINE, AND METHOD OF PREPARING THEREOF. |
| DE3537761A1 (en) * | 1985-10-24 | 1987-04-30 | Bayer Ag | INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUOR-1,4-DIHYDRO-4-OXO-7- (1-PIPERAZINYL) -QUINOLINE-3-CARBONIC ACID |
| DE68908786T2 (en) | 1988-06-16 | 1994-03-17 | Smith Kline French Lab | Condensed pyrimidine derivatives, processes and intermediates for their preparation and pharmaceutical preparations containing them. |
| FR2645152B1 (en) * | 1989-03-30 | 1991-05-31 | Lipha | 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM |
| US5043270A (en) | 1989-03-31 | 1991-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | Intronic overexpression vectors |
| CA2029651C (en) | 1989-11-17 | 2000-06-06 | David D. Davey | Tricyclic pteridinones and a process for their preparation |
| US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| TW274550B (en) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| CO4410191A1 (en) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | SYNTHESIS OF 3- [4- (2-AMINOETOXI) BENZOIL] -2-ARYL-6- HYDROXYBENZO [b] THIOPHENES |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| CZ289721B6 (en) * | 1995-05-19 | 2002-03-13 | Syngenta Participations Ag | Catalytic hydrogenation process of aromatic nitro compounds |
| US5698556A (en) * | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| CN1146567C (en) | 1996-09-23 | 2004-04-21 | 伊莱利利公司 | Olanzapine dihydrate D |
| SK1822001A3 (en) * | 1998-08-11 | 2002-08-06 | Pfizer Prod Inc | Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors |
| WO2001019825A1 (en) * | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| HUP0300136A2 (en) | 2000-03-06 | 2003-05-28 | Warner Lambert Co | 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| DE10018783A1 (en) | 2000-04-15 | 2001-10-25 | Fresenius Kabi De Gmbh | Stable aqueous ciprofloxacin infusion solutions containing sulfuric acid as the stabilizing agent useful for the treatment of bacterial infections in humans and animals |
| US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| DE10058119A1 (en) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Pharmaceutical kit containing repinotan, for use in acute treatment of neurological disorders such as stroke, including assay composition for determining body repinotan levels to optimize dosage |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| HRP20040213A2 (en) | 2001-09-04 | 2005-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| AU2002217111B2 (en) * | 2001-12-14 | 2007-05-31 | Merck Serono Sa | Methods of inducing ovulation using a non-polypeptide cAMP level modulator |
| HRP20041142A2 (en) | 2002-05-03 | 2005-10-31 | Schering Aktiengesellschaft | Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| CN1688576A (en) | 2002-08-08 | 2005-10-26 | 史密丝克莱恩比彻姆公司 | Thiophene compounds |
| US6862422B2 (en) * | 2003-02-12 | 2005-03-01 | Kabushiki Kaisha Toshiba | Image forming apparatus and image forming method having pressing members for pressing a belt-like member |
| HRP20050735B1 (en) | 2003-02-26 | 2013-08-31 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Dihydropteridinones, method for the production and use thereof in the form of drugs |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| US20040180898A1 (en) * | 2003-03-03 | 2004-09-16 | Bang-Chi Chen | Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines |
| MXPA05008526A (en) | 2003-03-26 | 2005-10-20 | Wyeth Corp | Immunogenic composition and methods. |
| WO2004093848A2 (en) | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| DE102004002557A1 (en) * | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of substituted pyrimido (5,4-d) pyrimidines for the treatment of respiratory diseases |
| JP2007517828A (en) * | 2004-01-17 | 2007-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of substituted pteridines to treat airway diseases |
| DE102004029784A1 (en) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments |
| DE102004033670A1 (en) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pyridodihydropyrazinone, process for its preparation and its use as a medicament |
| DE102004034623A1 (en) * | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 6-formyl-tetrahydropteridines, process for their preparation and their use as medicaments |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| EP1630163A1 (en) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, methods for their preparation and their use as drugs |
| EP1632493A1 (en) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridine derivatives, methods for their preparation and their use as drugs |
| WO2006021547A1 (en) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| EP1784406A1 (en) * | 2004-08-27 | 2007-05-16 | Boehringer Ingelheim International GmbH | Dihydropteridinones, process for their preparation and their use as drugs |
| DE102004058337A1 (en) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of fused piperazin-2-one derivatives |
| JP2009503014A (en) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dihydropteridinone in the treatment of respiratory diseases |
| US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2007102767A1 (en) | 2006-03-07 | 2007-09-13 | Astrazeneca Ab | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them |
| CA2695406A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
-
2004
- 2004-12-02 DE DE102004058337A patent/DE102004058337A1/en not_active Withdrawn
-
2005
- 2005-11-22 US US11/284,836 patent/US7238807B2/en not_active Ceased
- 2005-11-29 CN CN201010593286.0A patent/CN102093361B/en not_active Expired - Fee Related
- 2005-11-29 PL PL11189691T patent/PL2436685T3/en unknown
- 2005-11-29 NZ NZ556182A patent/NZ556182A/en not_active IP Right Cessation
- 2005-11-29 HR HRP20120980TT patent/HRP20120980T1/en unknown
- 2005-11-29 CA CA2588857A patent/CA2588857C/en not_active Expired - Fee Related
- 2005-11-29 MX MX2007006549A patent/MX2007006549A/en active IP Right Grant
- 2005-11-29 SI SI200531631T patent/SI1819706T1/en unknown
- 2005-11-29 PL PL05823799T patent/PL1819706T3/en unknown
- 2005-11-29 KR KR1020077015136A patent/KR101362131B1/en not_active Expired - Fee Related
- 2005-11-29 EP EP05823799A patent/EP1819706B1/en not_active Expired - Lifetime
- 2005-11-29 UY UY29233A patent/UY29233A1/en not_active Application Discontinuation
- 2005-11-29 SG SG200802431-7A patent/SG141461A1/en unknown
- 2005-11-29 RS RS20120519A patent/RS52533B/en unknown
- 2005-11-29 ES ES11189691.6T patent/ES2548680T3/en not_active Expired - Lifetime
- 2005-11-29 AU AU2005311308A patent/AU2005311308B2/en not_active Ceased
- 2005-11-29 ME MEP-2012-124A patent/ME01470B/en unknown
- 2005-11-29 BR BRPI0518601-3A patent/BRPI0518601A2/en not_active IP Right Cessation
- 2005-11-29 PT PT58237991T patent/PT1819706E/en unknown
- 2005-11-29 EA EA200701164A patent/EA012624B1/en not_active IP Right Cessation
- 2005-11-29 JP JP2007543838A patent/JP5164574B2/en not_active Expired - Lifetime
- 2005-11-29 DK DK11189691.6T patent/DK2436685T3/en active
- 2005-11-29 DK DK05823799.1T patent/DK1819706T3/en active
- 2005-11-29 CN CN2005800406546A patent/CN101065381B/en not_active Expired - Fee Related
- 2005-11-29 SG SG201000003-2A patent/SG158848A1/en unknown
- 2005-11-29 HU HUE11189691A patent/HUE027689T2/en unknown
- 2005-11-29 CN CN2010105934512A patent/CN102070637B/en not_active Expired - Fee Related
- 2005-11-29 KR KR1020127028659A patent/KR101395591B1/en not_active Expired - Fee Related
- 2005-11-29 ES ES05823799T patent/ES2395829T3/en not_active Expired - Lifetime
- 2005-11-29 EP EP11189691.6A patent/EP2436685B1/en not_active Expired - Lifetime
- 2005-11-29 WO PCT/EP2005/056291 patent/WO2006058876A1/en not_active Ceased
- 2005-11-29 UA UAA200706986A patent/UA89390C2/en unknown
- 2005-11-30 MY MYPI20055607A patent/MY147459A/en unknown
- 2005-11-30 PE PE2009000418A patent/PE20090488A1/en not_active Application Discontinuation
- 2005-11-30 PE PE2005001388A patent/PE20061061A1/en not_active Application Discontinuation
- 2005-12-01 TW TW094142312A patent/TWI362391B/en not_active IP Right Cessation
- 2005-12-02 AR ARP050105040A patent/AR053100A1/en unknown
-
2007
- 2007-04-25 ZA ZA200703368A patent/ZA200703368B/en unknown
- 2007-05-03 NO NO20072283A patent/NO20072283L/en not_active Application Discontinuation
- 2007-05-16 US US11/749,210 patent/US20070213531A1/en not_active Abandoned
- 2007-05-16 US US11/749,205 patent/US20070213529A1/en not_active Abandoned
- 2007-05-16 US US11/749,203 patent/US20070213528A1/en not_active Abandoned
- 2007-05-16 US US11/749,207 patent/US20070213534A1/en not_active Abandoned
- 2007-05-16 US US11/749,212 patent/US20070213530A1/en not_active Abandoned
- 2007-05-16 US US11/749,208 patent/US20070219369A1/en not_active Abandoned
- 2007-05-16 US US11/749,206 patent/US7626019B2/en active Active
- 2007-05-31 IL IL183568A patent/IL183568A/en not_active IP Right Cessation
-
2010
- 2010-08-05 US US12/850,993 patent/USRE43115E1/en not_active Expired - Lifetime
-
2012
- 2012-12-12 CY CY20121101215T patent/CY1113625T1/en unknown
-
2013
- 2013-10-09 CL CL2013002895A patent/CL2013002895A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI362391B (en) | Process for the manufacture of fused piperazin-2-one derivatives | |
| JP5923105B2 (en) | Chiral spiro-pyridylamidophosphine ligand compound, synthesis method thereof and use thereof | |
| JP2014214096A (en) | Method for producing novel organometallic complex and amine compound | |
| JP5387040B2 (en) | Method for optical resolution of alkylpiperidin-3-ylcarbamate and intermediates thereof | |
| CN114163375B (en) | Synthesis method of 6,6-dimethyl-3-azabicyclo [3.1.0] hexane or derivative thereof | |
| CN110002961B (en) | A kind of method of deracemization to synthesize chiral alcohol | |
| CN105934430B (en) | The method for preparing the formaldehyde of 1 alkyl, 3 difluoromethyl, 5 fluorine 1H pyrazoles 4 and the formic acid esters of 1 alkyl, 3 difluoromethyl, 5 fluorine 1H pyrazoles 4 | |
| WO2010122794A1 (en) | Process for production of pyrazinecarboxylic acid derivative, and intermediate for the production | |
| CN103111323B (en) | Chirality N, N-dialkyl-1, 2-diaminocyclohexane catalyst as well as preparation method and application thereof | |
| WO2000041997A1 (en) | Process for the preparation of optically active amino alcohols | |
| JP5529380B2 (en) | Sulfonated diphenylethylenediamine, process for its production and use in transfer hydrogenation catalysts | |
| CN108101740A (en) | A kind of method that fragrance alkynes one kettle way is directly translated into chiral alcohol | |
| CN108484580B (en) | A kind of preparation method of 3-acyloxy indole compounds | |
| CN101522634B (en) | Process for producing azabicycloalkanol derivatives | |
| WO2011157670A2 (en) | Novel process | |
| CN112851513B (en) | Synthetic method of 3-carbonyl 5-hydroxy ester compound | |
| CN113999201A (en) | Synthetic preparation method of nicotine | |
| WO2022135300A1 (en) | Synthesis and use of 1-benzyl-4-methyl-5-alkoxy-1,2,3,6-tetrahydropyridine derivative | |
| JP2003300993A (en) | New zero-valent ruthenium complex and method for producing the same | |
| JP5081146B2 (en) | Process for producing 1,2-phenylethane compounds using atom transfer radical coupling reaction | |
| JP2006151947A (en) | Production of linear compounds by dimerization of terminal olefins | |
| JP5382667B2 (en) | Production of cyclic compounds | |
| CN109988070A (en) | Intermediate of trans-1-hydroxy-1-(trifluoromethyl)-3-aminocyclobutane hydrochloride and preparation method and application | |
| CN116143688A (en) | A kind of preparation method of 3-piperidone compound | |
| JP4937442B2 (en) | Process for producing 5-fluorooxindole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |